Get the Stockscreener App
37.57
3.07%
1.04
Nektar Therapeutics stock is traded at $37.57, with a volume of 612.85K.
It is up +3.07% in the last 24 hours and down -15.32% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$36.53
Open:
$37.82
24h Volume:
612.85K
Relative Volume:
0.77
Market Cap:
$764.03M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-25.73
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-0.08%
1M Performance:
-15.32%
6M Performance:
+50.60%
1Y Performance:
+4,109%
1-Day Range:
$36.72
$39.75
1-Week Range:
$35.02
$39.75
52-Week Range:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
37.56 | 743.08M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Emerald Mutual Fund Advisers Trust Invests $13.27 Million in Nektar Therapeutics $NKTR - MarketBeat
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock - MarketBeat
Nektar Therapeutics’ chief R&D officer sells $137,935 in stock - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR - MarketBeat
NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight - Barchart.com
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story - Yahoo Finance
Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside - TipRanks
Corvus pill shows promise in early-stage eczema trial - statnews.com
Bond Watch: Should I buy Nektar Therapeutics stock nowJuly 2025 Technicals & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Fed Impact: Should I buy Nektar Therapeutics stock nowMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Nektar Therapeutics Stock Defies Short Sellers with Sharp Rally - AD HOC NEWS
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Short Interest in Nektar Therapeutics (NASDAQ:NKTR) Rises By 52.3% - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9%Still a Buy? - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.7%What's Next? - MarketBeat
History Review: Is Nektar Therapeutics stock a value trapTrade Entry Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Why the JP Morgan conference is important — but not make-or-break - statnews.com
BTIG maintains Nektar Therapeutics (NKTR) buy recommendation - MSN
Ignore Nektar Therapeutics stock in 2026 and load up on this one instead - MSN
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Trade Performance Summary & Step-by-Step Trade Execution Guides - ulpravda.ru
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
Q1 EPS Estimate for Nektar Therapeutics Raised by Analyst - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Here's why Nektar Therapeutics (NKTR) is a great momentum stock to buy - MSN
Nektar leaps a third on abuse-deterrent analgesic data - The Pharma Letter
Why Nektar Therapeutics stock remains on watchlists2025 Macro Impact & Advanced Swing Trade Entry Alerts - ulpravda.ru
Can Nektar Therapeutics stock sustain institutional interestJuly 2025 Earnings & Accurate Intraday Trading Signals - ulpravda.ru
Why analysts remain bullish on Nektar Therapeutics stockTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is Nektar Therapeutics stock a dividend growth opportunity2025 Trade Ideas & Precise Trade Entry Recommendations - ulpravda.ru
Is Nektar Therapeutics stock a buy in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Nektar promotions promised to drive growth of I-O pipeline - The Pharma Letter
Portfolio Shifts: Why Nektar Therapeutics ITH0 stock trades below fair valueJuly 2025 Trends & Expert Approved Trade Ideas - moha.gov.vn
Nektar TherapeuticsCommon Stock (NQ: NKTR - FinancialContent
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Yahoo Finance
Nektar Therapeutics Too Risky? This Biotech Stock Offers a Safer Bet - NAI500
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
New anxiety medications are in the pipeline for 2026 - AOL.com
FDA Leadership Stability Urged as Rare Disease Drug Approval Policies Expected to Show Results by 2026 - geneonline.com
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
What drives Nektar Therapeutics stock priceFinancial Sector Performance & Free Unlock Portfolio Growth - earlytimes.in
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):